This is a working overview of LC-MS/MS, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-04-25. Anything still debated is marked as such rather than presented as settled.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Sporting authorities added GW501516 to prohibited lists after it appeared in athlete samples and online markets. The World Anti-Doping Agency classifies it as a hormone and metabolic modulator, and its use can lead to an anti-doping rule violation. Some early laboratory work suggested effects on fatty acid oxidation and endurance-related metabolism in animals, but those findings do not establish safe or effective use in people. Reports of adverse events in humans are scarce and often anecdotal, which complicates risk assessment.
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
| Property | Value | Notes |
|---|---|---|
| Primary target | PPARδ (NR1C2) | Nuclear receptor involved in lipid metabolism |
| Preclinical effect | Increased fatty acid oxidation | Observed in rodent studies |
| Key safety signal | Tumors in rodents after long-term exposure | Contributed to halted clinical development |
| Human trial status | No approved product; development stopped | Limited short-term metabolic data |
| Sport regulatory status | Prohibited at all times | WADA hormone and metabolic modulators class |
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
The two substrates of this enzyme are L-α-glycerophosphoric acid, and oxidised nicotinamide adenine dinucleotide (NAD+). Its products are dihydroxyacetonephosphoric acid, reduced NADH, and a proton. The enzyme can also use the alternative cofactor, nicotinamide adenine dinucleotide phosphate. This enzyme belongs to the family of oxidoreductases, specifically those acting on the CH-OH group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is sn-glycerol-3-phosphate:NAD(P)+ 2-oxidoreductase. Other names in common use include L-glycerol-3-phosphate:NAD(P)+ oxidoreductase, glycerol phosphate dehydrogenase (nicotinamide adenine dinucleotide, (phosphate)), glycerol 3-phosphate dehydrogenase (NADP+), and glycerol-3-phosphate dehydrogenase [NAD(P)+]. This enzyme participates in glycerophospholipid metabolism.
Poland was established as a state under the Piast dynasty, which ruled the country between the 10th and 14th centuries. Historical records referring to the Polish state begin with the rule of Duke Mieszko I, whose reign commenced sometime before 963 and continued until his death in 992. Mieszko converted to Christianity in 966, following his marriage to Princess Doubravka of Bohemia, a fervent Christian. The event is known as the "baptism of Poland", and its date is often used to mark a symbolic beginning of Polish statehood. Mieszko completed a unification of the Lechitic tribal lands that was fundamental to the new country's existence. Following its emergence, Poland was led by a series of rulers who converted the population to Christianity, created a strong kingdom and fostered a distinctive Polish culture that was integrated into the broader European culture.
=== Cooking === Chilies with a low capsaicin content can be cooked like bell peppers, for example stuffing and roasting them. Hotter varieties need to be handled with care to avoid contact with skin or eyes; washing does not efficiently remove capsaicin from skin. Chilies can be roasted over very hot coals or grilled for a short time, as they break up if overcooked. The leaves of every species of Capsicum are edible, being mildly bitter and nowhere near as hot as the fruits. They are cooked as greens in Filipino cuisine, where they are called dahon ng sili (literally "chili leaves"). They are used in the chicken soup tinola. In Korean cuisine, the leaves may be used in kimchi.
==== Schizophrenia ==== Modafinil and armodafinil were studied as a complement to antipsychotic medications in the treatment of schizophrenia. They showed no effect on positive symptoms or cognitive performance. A 2015 meta-analysis found that modafinil and armodafinil may slightly reduce negative symptoms in people with acute schizophrenia, though they do not appear useful for people with stable schizophrenia who have prominent negative symptoms (such as reduced motivation or social withdrawal). Among medications demonstrated to be effective for reducing negative symptoms in combination with antipsychotics, modafinil, and armodafinil are among the smallest effect sizes.
Sources: en.wikipedia.org
== Diagnosis == Assessment of diabetic foot ulcer includes identifying risk factors such as diabetic peripheral neuropathy, noting that 50 percent of people are asymptomatic, and ruling out other causes of peripheral neuropathy, such as alcohol use disorder and spinal injury. Diabetic foot ulcers are often misdiagnosed in patients with undiagnosed skin malignancies, especially high-risk in elderly patients. The location of the ulcer, its size, shape, depth, and whether the tissue is granulating or not need to be considered. Further considerations include whether there is malodour, condition of the border of the wound, and palpable bone and sinus formation should be investigated. Signs of infection require to be considered, such as the development of grey or yellow tissue, purulent discharge, unpleasant smell, sinus, undermined edges, and exposure of bone or tendon.
Cetacaine is a topical anesthetic that contains the active ingredients benzocaine (14%), butamben (2%), and tetracaine hydrochloride (2%). Cetacaine also contains small amounts of benzalkonium chloride at 0.5% and 0.005% of cetyl dimethyl ethyl ammonium bromide all in a bland water-soluble base. Although Cetacaine has been widely used in the medical and dental fields, it has yet to be officially approved by the FDA. Cetacaine is produced by the company Cetylite Industries, Inc. and they provide Cetacaine in three forms: liquid, gel, and spray.
== Research contributions == Esimone pioneered research in the use of recombinant viral vectors as surrogates for high-throughput antiviral screening studies, as well as on the use of indigenous medicinal plants as immunomodulators, vaccine adjuvants, and anti-infectives. The vector-based antiviral screening technique developed by Esimone between 2003 and 2005 in Germany significantly revolutionized high-throughput screening for anti-HIV compounds worldwide. In addition to this work, his research led to the discovery of new antimicrobial compounds—including antibacterial, antifungal, and antiviral agents—derived from endophytes, lichens, ferns, herbs, and spices. Esimone was instrumental in the isolation and characterization of resistance genes from clinical settings, abattoirs, and poultry, with a particular focus on extended-spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs) identified in the southeastern regions of Nigeria. His team became the first to demonstrate the presence of ESBL-producing bacteria harboring the CTXM-15 gene, which confers resistance to third-generation cephalosporins in Nigeria. Additionally, they were the first to identify MBL-producing bacteria containing the blaIMP-1 and blaVIM-1 genes within poultry and abattoirs in southeastern Nigeria. They also reported the increasing frequency of MBL-producing Klebsiella, Pseudomonas, and Escherichia species in the country.
Sources: en.wikipedia.org
== Evolution == It is believed that components of the citric acid cycle were derived from anaerobic bacteria, and that the TCA cycle itself may have evolved more than once. It may even predate biosis: the substrates appear to undergo most of the reactions spontaneously in the presence of persulfate radicals. Alternatively, prebiotic synthesis of the citric acid cycle could have beginnings in the interstellar medium. Theoretically, several alternatives to the TCA cycle exist; however, the TCA cycle appears to be the most efficient. If several TCA alternatives had evolved independently, they all appear to have converged to the TCA cycle.
The result of the Jeddah talks was an Iraqi demand for $10 billion to cover the lost revenues from Rumaila. Kuwait offered $500 million. The Iraqi response was to immediately order an invasion, which started on 2 August 1990 with the bombing of Kuwait's capital, Kuwait City. Before the invasion, the Kuwaiti military was believed to have numbered 16,000 men, arranged into three armored, one mechanized infantry and one under-strength artillery brigade. The pre-war strength of the Kuwait Air Force was around 2,200 Kuwaiti personnel, with 80 fixed-wing aircraft and 40 helicopters. In spite of Iraqi sabre-rattling, Kuwait did not mobilize its force; the army had been stood-down on 19 July, and during the Iraqi invasion many Kuwaiti military personnel were on leave. By 1988, at the end of the Iran–Iraq war, the Iraqi Army was the world's fourth largest army, consisting of 955,000 standing soldiers and 650,000 paramilitary forces in the Popular Army. A low estimate shows the Iraqi Army capable of fielding 4,500 tanks, 484 combat aircraft and 232 combat helicopters. A high estimate shows the Iraqi Army capable of fielding one million troops and 850,000 reservists, 5,500 tanks, 3,000 artillery pieces, 700 combat aircraft and helicopters; it held 53 divisions, 20 special-forces brigades, and several regional militias, and had a strong air defense.
=== GPR139 receptor === Big dynorphin is one of the activators of the GPR139, a G protein-coupled receptor (GPCR), recently deorphanized as a dynorphin receptor. In a wide neuropeptide library screen it exhibited one of the highest efficacies among prodynorphin-derived peptides. At low concentrations, dynorphins predominantly activate canonical opioid receptors (KOR, MOR, DOR), while at higher concentrations, they additionally recruit GPR139. This receptor couples to Gq/11 G protein-mediated signaling, which is mechanistically opposite to the Gi/o inhibitory signaling of classical opioid receptors. This permits GPR139 to function as a molecular homeostatic brake: when dynorphin reaches high concentrations during intense stress or pain, simultaneous GPR139 activation counteracts excessive opioid receptor signaling through excitatory signaling pathways, preventing pathological over-inhibition of neuronal activity.
Singer noted in 1949 that Psilocybe cubensis had psychoactive properties. In Australia, the use of psychoactive mushrooms grew rapidly between 1969 and 1975. In a 1992 paper, locals and tourists in Thailand were reported to consume P. cubensis and related species in mushroom omelets—particularly in Ko Samui and Ko Pha-ngan. At times, omelets were adulterated with LSD, resulting in prolonged intoxication. A thriving subculture had developed in the region. Other localities, such as Hat Yai, Ko Samet, and Chiang Mai, also had some reported usage. In 1996, jars of honey containing Psilocybe cubensis were confiscated at the Dutch-German border. Upon examination, it was revealed that jars of honey containing psychedelic mushrooms were being sold at Dutch coffee shops. P. cubensis is one of the most widely known of the psilocybin-containing mushrooms used for triggering psychedelic experiences after ingestion. Its major alkaloids are:
Sources: en.wikipedia.org
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.
Small short-term human trials examined metabolic markers such as lipids and glucose. The trials did not continue after rodent cancer findings, so long-term human safety is unknown.
Controlled human trials have not established a performance benefit. Anecdotal reports exist, but they are not reliable evidence.
No. Major drug regulators have not approved GW501516 for treating any medical condition. Products sold as cardarine are typically unapproved research chemicals or supplements, so their contents and safety are not assured.